article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

One aspect that is extremely promising about radiopharmaceutical therapeutics is that they do not give a patient the side effects that are commonly experienced with chemotherapy. Hoppin served as lead director of Noria as the two organisations were sold to Bayer Healthcare in June of 2021.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience.

article thumbnail

Beating the Big C

Pharmaceutical Technology

” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.” “There’s a huge clinical need which has been undelivered for years,” says Gustav Ando, manager of the healthcare business development unit [HBDU] at Global Insight. We’re on the right path.”